Understand · Treat · Recover

Types and Biology of Gastric Cancer

The pathology report identifies the disease being treated. Tumours in the same organ can require very different care.

For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.

This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.

Chapter 4 of 20

Intestinal and diffuse patterns

Intestinal-type adenocarcinoma tends to form glands. Diffuse-type disease has less cohesive cells and can thicken the stomach wall without a sharply defined lump. Linitis plastica describes a stiff, diffusely infiltrated stomach; deep or repeat sampling may be needed when surface biopsies do not explain a suspicious appearance. Signet-ring cells are one form of poorly cohesive cells and can occur in different proportions.

Grade is different from stage

Grade describes how abnormal or poorly organised the cells appear. Stage describes invasion and spread. A high-grade tumour is not automatically metastatic. Histology can influence patterns of spread and clinical planning, but no single adjective in a report can predict an individual outcome. A specialist pathology review is valuable when the diagnosis is unusual or the biopsy is limited.

Other stomach malignancies

DiseaseWhy a separate pathway is needed
Gastric lymphomaArises from immune cells. Some MALT lymphomas respond to H. pylori eradication; aggressive lymphomas need lymphoma-specific treatment.
GISTArises from supporting tissue. KIT/PDGFRA biology and surgical risk influence targeted therapy.
Neuroendocrine neoplasmDifferentiation, grade, proliferation and type determine care; an indolent tumour differs greatly from high-grade neuroendocrine carcinoma.

FLOT and the gastric adenocarcinoma biomarker algorithm should not automatically be applied to these diseases.

Molecular subtypes

Research classifications describe Epstein–Barr virus-associated, microsatellite-unstable, genomically stable and chromosomally unstable gastric cancers. They help explain biological diversity. Routine treatment decisions are more directly supported by specific validated tests such as HER2, mismatch repair/MSI, PD-L1 and CLDN18.2. Being in a research subtype is not by itself a prescription for a particular drug.

Why two samples may differ

Tumour heterogeneity means different parts of a cancer may not have identical features. A small biopsy can miss a positive area, and treatment can change the tumour over time. If a result is unexpected or a new treatment depends on a marker, the team may review tissue quality or obtain another sample. Ask which findings are confirmed and which remain uncertain.

Key takeaways

Confirm the tumour type before choosing an adenocarcinoma treatment pathway.

Frequently asked questions

Are all stomach cancers adenocarcinomas?

No. Lymphoma, GIST and neuroendocrine malignancies are important alternatives.

Does poorly differentiated mean incurable?

No. It describes grade, not whether complete treatment is possible.

Is signet-ring cancer always treated differently?

It influences assessment, but treatment still depends on stage, location, biomarkers and fitness.

What is linitis plastica?

A pattern of diffuse infiltration that makes the stomach wall thick and less flexible.

Does EBV positivity automatically qualify for immunotherapy?

No. Eligibility must follow a validated indication; EBV alone is not a universal treatment selector.

When should pathology be reviewed?

When findings are unusual, incomplete or inconsistent with imaging, or a major treatment decision depends on them.

References and further reading